Colin is the Founder and CEO of Greater Bay Biotechnology (GBBT), which focuses on the research, development and commercialisation of transdermal drug and cell delivery and diagnostic technology with wide applications including the treatment of diseases (e.g. diabetes, cancer, psoriasis) and skincare. Prior to his current position, Colin has worked in senior roles at Global 500 enterprises including EY, ANZ Bank, Standard Chartered and he has advised major shareholders of listed companies in the biotechnology and pharmaceutical sectors on strategy, corporate development, incubation and IPO.

Colin NG

Founder & CEO